...
首页> 外文期刊>Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis >Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.
【24h】

Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.

机译:骨髓增生性肿瘤患者血小板和巨核细胞中Dkk3蛋白表达增加。

获取原文
获取原文并翻译 | 示例

摘要

Dickkopf-3 (Dkk3) has been proposed as tumour suppressor gene and a marker for tumour blood vessels. We analysed the expression and function of Dkk3 in platelets and megakaryocytes from healthy controls and patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN). Dkk3 protein and gene expression in platelets was compared with endothelial and other blood cell populations by ELISA, real-time PCR, and immunofluorescence. Moreover, megakaryocytes were isolated from bone marrow aspirates by CD61 microbeads. Immunohistochemical studies of Dkk3 expression were performed in essential thrombocythemia (ET), polycythemia vera (PV), primary myelofibrosis (PMF) and control reactive bone marrow cases (each n=10). Compared to all other blood cell populations platelets showed the highest concentration of Dkk3 protein (150 +/- 19 ng/mg total protein). A strong DKK3 gene and protein expression was also observed in isolated megakaryocytes. Dkk3 co-localised with VEGF in alpha-granules of platelets and was released similar to VEGF upon stimulation. Addition of recombinant Dkk3 had no influence on blood coagulation (aPTT, INR) and platelet aggregation. Significantly more Dkk3+ megakaryocytes/mm2 could be found in bone marrow biopsies from patients with MPN (ET 40 +/- 10, PV 31 +/- 4, PMF 22 +/- 3) than in controls (15 +/- 3). The mean proportion of Dkk3+ megakaryocytes was increased in MPN as well (ET 83% +/- 15%; PV 84% +/- 12%; PMF 77% +/- 8%) compared to controls (53% +/- 11%). Dkk3+ megakaryocytes correlated with microvessel density in PV and PMF. We conclude that Dkk3 might be involved in the pathogenesis of MPN.
机译:已经提出了Dickkopf-3(Dkk3)作为肿瘤抑制基因和肿瘤血管的标志物。我们分析了Dkk3在健康对照和BCR-ABL1阴性骨髓增生性肿瘤(MPN)患者的血小板和巨核细胞中的表达和功能。通过ELISA,实时PCR和免疫荧光将血小板中Dkk3蛋白和基因表达与内皮细胞和其他血细胞群体进行了比较。此外,通过CD61微珠从骨髓抽吸物中分离出巨核细胞。 Dkk3表达的免疫组织化学研究在原发性血小板增多症(ET),真性红细胞增多症(PV),原发性骨髓纤维化(PMF)和对照反应性骨髓病例(每例n = 10)中进行。与所有其他血细胞群体相比,血小板显示出最高浓度的Dkk3蛋白(总蛋白150 +/- 19 ng / mg)。在分离的巨核细胞中也观察到了强的DKK3基因和蛋白质表达。 Dkk3与VEGF在血小板的α颗粒中共定位,并在刺激后类似于VEGF释放。添加重组Dkk3对凝血(aPTT,INR)和血小板聚集没有影响。与对照组(15 +/- 3)相比,MPN患者(ET 40 +/- 10,PV 31 +/- 4,PMF 22 +/- 3)的骨髓活检中发现的Dkk3 +巨核细胞/ mm2多得多。与对照组(53%+/- 11)相比,MPN中Dkk3 +巨核细胞的平均比例也有所增加(ET 83%+/- 15%; PV 84%+/- 12%; PMF 77%+/- 8%)。 %)。 Dkk3 +巨核细胞与PV和PMF中的微血管密度相关。我们得出结论,Dkk3可能与MPN的发病机制有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号